{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:27:03Z","timestamp":1786678023137,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtocrr.2026.101029","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:40:51Z","timestamp":1780332051000},"page":"101029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1"],"prefix":"10.1016","volume":"7","author":[{"given":"Marina Chiara","family":"Garassino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Baramidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Gogishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Nechaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo Fuang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Kulyaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasimova","family":"Zyuhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana-Ioana","family":"Scheusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.G.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manika","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Seebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Magnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101029_bib1","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41598-021-81666-x","article-title":"Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtocrr.2026.101029_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.10.008","article-title":"Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study","volume":"150","author":"Bersanelli","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101029_bib3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/1759-7714.14403","article-title":"Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: a retrospective study","volume":"13","author":"Heraudet","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2026.101029_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101029_bib5","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2026.101029_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101029_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101029_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2025.03.033","article-title":"Cemiplimab monotherapy for first-line treatment of patients with advanced NSCLC with PD-L1 expression of 50% or higher: five-year outcomes of EMPOWER-Lung 1","volume":"20","author":"Kilickap","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101029_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101029_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12582","article-title":"Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance","volume":"280","author":"Bloy","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtocrr.2026.101029_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtocrr.2026.101029_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00262-012-1390-6","article-title":"Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer","volume":"62","author":"Ramakrishnan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2026.101029_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101029_bib14","unstructured":"ClinicalTrials.gov. Identifier NCT03793179: testing the timing of pembrolizumab alone or with chemotherapy as first line treatment and maintenance in non-small cell lung cancer (INSIGNA; EA5163\/S1709). Accessed April 27, 2026."}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:33:26Z","timestamp":1786674806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666364326000809"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101029","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101029"}}